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Abstract—To test the hypothesis that local vascular production of angiotensin II is necessary for the normal regulation of 
blood pressure, we engineered a new line of genetically altered mice that lack endothelial angiotensin-converting 
enzyme (ACE). This was accomplished using a novel strategy of targeted homologous recombination to separate the 
transcriptional control of somatic ACE from its endogenous promoter and to substitute control to the albumin promoter. 
These new mice, termed ACE.3, do not produce ACE within the lung, the aorta, or any vascular structure. ACE activity 
within the kidney is only about 14% that of wild-type mice and is limited to tubular epithelium. In contrast, hepatic ACE 
expression in ACE.3 mice is about 87-fold that of wild-type. The blood pressure, plasma angiotensin II levels, response 
to ACE inhibitors, and renal function of ACE.3_/_ mice are indistinguishable from littermate wild-type mice. These data 
show that, under basal conditions, the normal regulation of blood pressure and renal function is possible in a mouse 
devoid of endothelial ACE. (Circ Res. 2002;90:87-92.)
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T he renin-angiotensin system plays a central role in 
controlling mammalian blood pressure: mice with a 
genetic block of this system have systolic blood pressures 
35 mmHg lower than control animals.1-3 Less clear is 
whether this system functions as a systemic endocrine net­
work or whether it functions more as a series of local 
autocrine/paracrine networks within various organs and seg­
ments of the vasculature.4 Indeed, some (including us) have 
hypothesized that the local production of angiotensin II by 
endothelial-bound angiotensin-converting enzyme (ACE) is a 
critical feature of normal vascular function.3 5 To test the 
hypothesis that local vascular production of angiotensin II is 
necessary for the normal regulation of blood pressure, we 
genetically altered mice to lack endothelial ACE. This was 
accomplished using a novel strategy of targeted homologous 
recombination to separate the transcriptional control of so­
matic ACE from its endogenous promoter and to substitute 
control to the albumin promoter. These new mice, termed 
ACE.3, produce ACE within hepatocytes but do not make 
ACE within the lung, the aorta, or any vascular structure. 
Surprisingly, the expression of ACE by the liver is capable of 
substituting for endothelial ACE expression in that ACE.3 / 
mice have a normal blood pressure and normal renal function.
Materials and Methods 
Creation of Homozygous Mutant Mice
A 10.7-kb fragment o f mouse genomic DNA was cloned from a 
mouse CC1.2 embryonic stem (ES) cell library derived from mouse
strain 129 DNA. This contained 2.4 kb of the somatic ACE 
promoter, the somatic ACE transcription start site, and 8.3 kb of 
genomic sequence encompassing somatic ACE exons 1 through 12. 
Using a unique BssHII restriction site, a neomycin cassette was 
inserted 3 to the somatic ACE transcriptional start site but 5  to 
somatic ACE exon 1. Next, a 2.3-kb albumin promoter/enhancer was 
placed immediately 3 to the neomycin cassette. The albumin 
promoter/enhancer, termed NB, was a gift o f Dr Richard Palmiter 
(University o f Washington). Animal care was supervised by the 
Emory University Division of Animal Research and followed ac­
cepted practices o f the American Veterinary Medical Association.
The targeting construct was linearized and electroporated into R1 
ES cells. These cells were derived from a 129/SVX129/SvJ F1 
embryo.6 After positive and negative selection, individual ES cell 
clones were isolated and screened for targeted homologous recom­
bination using a strategy of polymerase chain reaction (PCR) and 
genomic Southern blot analysis. The generation o f chimeric, hetero­
zygote, and homozygous mutant mice was performed as previously 
described.23 Blastocysts were obtained from C57Bl/6 mice. Chi­
meric mice were mated to C57Bl/6 mice. All studies were performed 
on F2 generation litters generated from the breeding of F1 heterozy­
gous animals (ACE / ).
Genotyping
PCR genotyping of genomic DNA relied on 2 separate reactions to 
amplify a wild-type-specific and a mutant-specific fragment. The 
wild-type reaction used a primer pair flanking the site o f insertion of 
the 3.1-kb neomycin and the 2.3-kb albumin promoter cassettes. The 
prim ers 5 -A C T T T G G A G C G A G G A G G A A G C -3  and 5 -  
AACAGCACCAGCAGCGACAGCATCAA-3' yielded a 213-bp 
product from wild-type genomic DNA. To detect the mutant allele, 
a forward prim er (5 -CTCTACAGATTAATTCAGTACAG-3 ) 
from the neomycin cassette was paired with a reverse primer from
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the albumin promoter (5 '-AAGTGGAATGAGCAAGCAGAA-3'). 
These amplified a fragment of approximately 500 bp.
For Southern blot analysis, DNA was digested to completion with 
the restriction enzyme Tth111I  and was probed with a 1.1-kb 
genomic ACE fragment from the region immediately 3 to the 
targeting construct. This probe hybridizes to the ACE gene but not to 
the targeting construct. The mutant allele gave rise to a band of 
approximately 10 kb, whereas the wild-type allele gave rise to a band 
of > 2 0  kb.
ACE Activity
ACE activity was measured using the ACE-REA kit from American 
Laboratory Products Company, Ltd (ALPCO). ACE activity was 
defined as that inhibitable by lisinopril. For the determination of 
tissue ACE activity, mice were euthanized under anesthesia and their 
organs were weighed and frozen in liquid nitrogen. Later, each organ 
was gently homogenized in ACE homogenization buffer (50 mmol 
HEPES, pH 7.4, 150 mmol NaCl, 25 jumol ZnCl2, and 1 mmol 
AEBSF) lacking detergent. These homogenates were centrifuged at
10 000g and the supernatant discarded. The pellets were resuspended 
in ACE homogenization buffer containing 0.5% Triton X-100 and 
vigorously rehomogenized. Total organ ACE was then calculated 
using the known weight of the whole organ. Total plasma volume 
was estimated as 26.6 ju,L per gram of animal.7
Western Blotting and Immunohistochemistry
Samples for W estern blotting were homogenized in ACE homoge- 
nization buffer containing 0.5% Triton X-100. Equivalent amounts 
o f protein were then separated by SDS-PAGE on a 10% gel. The 
membranes were probed with a 1:250 dilution of a rabbit polyclonal 
anti-mouse ACE antibody and exposed to film using enhanced 
chemiluminescence.
Tissue samples were taken at euthanasia and preserved either in 
B ouin’s fixative or 10% buffered formalin. They were then embed­
ded in paraffin and prepared for immunohistochemistry using stan­
dard techniques. ACE was detected using a rabbit polyclonal 
anti-mouse ACE antibody diluted 1:400 and immunoperoxidase as 
previously described.8
Plasma Angiotensin I and II
Mice were exsanguinated by cardiac puncture, and blood was 
collected on ice in tubes containing 1.6 mg/mL potassium-EDTA, 
100 jumol/L amastatin, 100 jumol/L bestatin, and 4 jug/mL lisino­
pril.7 Plasma was immediately frozen and stored at — 80°C. Angio­
tensin I and II levels were measured by radioimmunoassay as 
previously described.9 The assay background was determined by 
measuring peptide levels in angiotensinogen knockout mice, animals 
genetically modified to lack angiotensin I and angiotensin II. 
Background values were subtracted from the ACE.3 measurements 
to obtain the final data.
Blood Pressure
Systolic blood pressure was measured using a Visitech Systems 
BP2000 automated tail cuff system as previously described.2 To 
measure the blood pressure response to captopril, a baseline blood 
pressure (day 0) was determined for each mouse. At the end of day
0 , captopril was added to the drinking water at an appropriate 
concentration to deliver 50 mg/kg of drug each day to each mouse. 
For each of the next 5 days, 25 measurements of systolic blood 
pressure were recorded for each animal. The first 5 were discarded 
and the next 20 were averaged. Fresh captopril solution was added at 
the end of days 2 and 4. At the end of day 5, the captopril was 
replaced with tap water, and blood pressure measurements were 
continued for 4 subsequent days.
Hematocrit and Urine Collection
To measure hematocrit, mice were bled from the tail vein and blood 
collected in microcapillary tubes. These were centrifuged for 4 
minutes at 12 000g and read in a manual microcapillary reader. For 
urine collection, littermate mice were first deprived of water in their
cages for 6 hours. They were then kept without food or water for 24 
hours in individual metabolic chambers that separated urine from 
feces. Mineral oil was placed in the urine collection vial to minimize 
evaporation. At the end of the 24-hour collection period, the total 
urine output was measured and urine osmolality determined using a 
W escat 5500 Vapor Pressure Osmometer (Wescor Inc).
Results
To create mice that only express ACE within the liver, we 
made a targeting construct in which a neomycin resistance 
cassette (KT3NP4) and an albumin promoter/enhancer were 
inserted between the transcription and the translation start 
sites for somatic ACE (Figure 1A).1011 The neomycin cas­
sette contains the antibiotic resistance gene and exon 9 from 
the mouse hypoxanthine phosphoribosyltransferase gene. 
This exon encodes a strong transcriptional termination signal 
and was oriented to terminate transcription initiated by the 
somatic ACE promoter. Thus, the targeting construct is 
designed to substitute control of somatic ACE transcription 
from the somatic ACE promoter to the albumin promoter.
Mice homozygous for the ACE.3 mutation ( / , knock­
out) were created using targeted homologous recombination 
in embryonic stem cells. Proper homologous recombination 
was identified using a combined strategy of PCR and 
genomic Southern blot analysis (Figure 1B). ACE.3 / mice 
have normal serum electrolytes including normal serum 
potassium and creatinine levels. They show a very mild 
elevation of liver-derived serum transaminases (serum 
glutamic-oxaloacetic transaminase [U/L]: wild-type 67±5, 
heterozygous 85±10, and knockout 118±20; serum gluta­
mate pyruvate transaminase [U/L]: wild-type 29±3, het­
erozygous 27 4, and knockout 47 8) (n 5). However, as 
discussed below, the knockout animals have a normal liver 
histology.
Tissue Distribution of ACE
To evaluate the change in tissue ACE distribution, age 
matched ACE.3+/+ and ACE.3_/_ mice were euthanized, and 
tissue homogenates were analyzed by Western blot using a 
rabbit polyclonal anti-mouse ACE antibody (Figure 2A). A 
wild-type mouse produces very little ACE within the liver. In 
contrast, the ACE.3_/_ mice demonstrate significant hepatic 
ACE expression. A wild-type mouse contains an enormous 
amount of ACE in the lung due to the high content of 
endothelium within this organ. In comparison, the ACE.3 / 
mice have virtually no ACE expression within the lung. 
Indeed, ACE.3_/_ mice showed no ACE in the heart, aorta, 
intestine, striated muscle, and seminal vesicles, all organs in 
which ACE.3+/+ mice have easily identifiable levels of ACE. 
As anticipated, testis ACE production was not altered in the 
ACE.3_/_ mice because this isozyme is due to an intragenic 
promoter unmodified by the targeting construct. In contrast, 
the production of ACE by somatic tissues (Leydig and 
endothelial cells) within the testis was not observed in the 
ACE.3_/_ mice.
To quantitate organ specific ACE expression, a large 
cohort of animals was euthanized, and individual organs were 
homogenized using a protocol that permitted evaluation of 
tissue ACE activity in a preparation relatively free of plasma 
contamination. Total organ ACE activity, normalized for the
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Figure 1, ACE.3 targeting construct. A, Top, Wild-type organiza­
tion of the ACE locus. Both the somatic ACE promoter and the 
testis ACE promoter are indicated with arrows. A unique BssHII 
restriction site is located between the transcription start site and 
the translation start site of somatic ACE. The start site for testis 
ACE transcription is indicated by a box between the 12th and 
13th exons of somatic ACE. The targeting construct used for 
homologous recombination (middle) contained 10.7 kb of 
homologous genomic DNA organized into left and right arms of 
2.4 and 8.3 kb. Between these arms, we incorporated the 
3.1-kb KT3NP4 neomycin resistance cassette (Neo*) and the 
2.3-kb albumin promoter such that the structural portion of the 
ACE gene would now be under the control of the albumin pro­
moter. Effects of the somatic ACE promoter were minimized by 
positioning the neomycin cassette such that any transcripts 
generated by this promoter would terminate within the neomycin 
construct. A thymidine kinase (TK) cassette was positioned 5' to 
the 2.4-kb homology arm. With proper homologous recombina­
tion, this will not be incorporated within the modified ACE allele 
(bottom). A unique Tth 1111 restriction site within the targeting 
construct is indicated by Tth. B, Southern blot analysis.
Genomic DNA from wild-type (+/+), heterozygous (+ /-), and 
ACE.3 knockout ( - / - )  mice was digested with 7V?111I and was 
probed with a 1.1-kb genomic ACE fragment from the region 
immediately 3' to the targeting construct. This probe hybridizes 
to the ACE gene but not to the targeting construct. The mutant 
allele gave rise to a band of approximately 10 kb, whereas the 
wild-type allele gave rise to a band of >20 kb.
weight of individual animals, was then calculated for each 
genotype (Figure 2B). Although A C E . 3 m i c e  have internal 
organs equivalent in weight to littermate wild-type mice, 
there is a marked change in the organ distribution of ACE
activity. ACE.3_/_ mice have approximately 87-fold more 
hepatic ACE activity than the ACE activity present in the 
livers of wild-type mice. The opposite was true for lung 
where no ACE activity was detected in the lung homogenates 
of the ACE.3_/_ mice. Evaluation of ACE activity in 
ACE.3_/_ kidney showed levels approximately 14% that 
observed in the kidneys of wild-type mice. When evaluated as 
activity per jtg of solubilized protein, this figure was 12.5% 
of wild-type. Other somatic tissues, including the aorta, heart, 
and small intestine, showed a complete lack of ACE activity 
in ACE.3 / mice (data not shown). ACE.3 / mice have 
approximately 80% the plasma ACE activity of wild-type 
mice. Total plasma ACE activity, per animal, was estimated 
to be about 11% the total ACE activity present in liver. We 
hypothesize that the plasma ACE present in ACE.3 _/_ mice 
results from the proteolytic release of ACE from the surface 
of hepatocytes.
Immunohistochemistry was used to evaluate the tissue 
patterns of ACE expression in the liver, lung, and kidney of 
ACE.3 mice (Figure 3). Although livers from wild-type 
animals show very little ACE expression (Figure 3A), abun­
dant immunostaining was present in the cell membranes of 
hepatocytes from the ACE.3 knockout mice (Figure 3B). In 
contrast, the lungs of the ACE.3_/_ mice lacked any staining 
for ACE, whereas abundant ACE expression was evident in 
its wild-type counterpart (Figures 3C and 3D). Figures 3E and 
3F show representative staining from the kidneys of ACE.3 
wild-type and ACE.3 / animals. Whereas the kidneys of the 
wild-type mouse showed intense staining for ACE in the 
straight portion of the proximal tubule (predominantly the S3 
segment), equivalent epithelium in ACE.3_/_ mice showed 
markedly reduced levels of staining. Instead, the ACE.3_/_ 
kidneys showed a very low level of ACE expression through­
out the proximal tubule.
We also carefully evaluated the kidneys of ACE.3_/_ mice 
to assess whether residual ACE activity was due, in part, to 
ACE expression by renal blood vessels. For this study, 
portions of kidney from both wild-type and ACE.3_/_ mice 
were incorporated into the same paraffin blocks and were 
processed on the same slides. As expected, the vascular 
endothelium of wild-type mice was intensely positive for 
ACE expression (Figure 3G, arrow). In contrast, endothelium 
from blood vessels of ACE.3_/_ mice exhibited no such ACE 
expression (Figure 3H). Vascular adventitia showed a similar 
pattern with staining for ACE in wild-type blood vessels but 
none in the ACE.3_/_ mice.
Physiological Analysis
Next, we measured systolic blood pressure to determine 
whether the ACE expression in ACE.3_/_ mice could com­
pensate for the lack of endothelial expression in these animals 
(Figure 4A). Pressure was determined using a computerized 
tailcuff manometer after extensive training of the animals.12 
A cohort of 48 littermate ACE.3 mice showed no differences 
in blood pressure between wild-type, heterozygous, and 
ACE.3_/_ mice. Thus, ACE.3_/_ mice, while lacking endo­
thelial ACE, have no difficulty maintaining a normal systolic 
blood pressure. Although it is currently impossible to quan­
titate the contribution of residual proximal tubular ACE to the
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mice for the + /+  and - / -  kidney, 16 to 18 mice for each plasma ACE genotype.
Figure 2, Tissue ACE expression. A, ACE.3 wild- 
type {+/+) and knockout ( - / - )  mice were eutha­
nized, and organ extracts were analyzed by West­
ern blot using a rabbit anti-mouse ACE antibody. 
Somatic ACE is detected as a protein of approxi­
mately 170 kDa, whereas testis ACE is a more dif­
fuse band centered around 95 kDa. The organs 
studied were liver, lung, heart, spleen (spl), kidney 
(kid), aorta, small intestine (S Int), large intestine (L 
Int), striated muscle (Mus), brain, seminal vesicles 
(SV), and testis. Wild-type mice have little ACE in 
the liver but abundant ACE in the lung. In contrast, 
the ACE.3 A mice have significant liver ACE but 
virtually no ACE protein in the lung, aorta, heart, 
gut, muscle, and seminal vesicles. The kidney of 
ACE.3 A mice does have residual somatic ACE 
expression. The testis of ACE.3 A mice expressed 
no somatic ACE but continued to produce abun­
dant testis ACE. B, ACE.3 wild-type (black), het­
erozygote (gray), and knockout (stippled) mice 
were euthanized and ACE activity measured in 
organ homogenates. Total organ ACE activity was 
then calculated for the liver, lungs, kidneys, and 
plasma of each mouse and normalized for the 
mass of the mouse. The livers of ACE.3 A mice 
have abundant total ACE activity, due in part to 
the large size of this organ. In contrast, ACE.3 A 
mice have no detectable ACE activity in lung. 
ACE.3 A mice have about 14% of the renal ACE 
found in wild-type mice. The data are the average 
of 5 or 6 individual mice with these exceptions: 11 
All data presented are the group mean±SEM.
blood pressure regulation of the A C E . 3 m i c e ,  it is clear 
that endothelial ACE is not required for this precise control.
In order to get mechanistic insight into the blood pressure 
observed in the A C E . 3 m i c e ,  we investigated plasma 
angiotensin peptide levels. This study showed no significant 
difference in plasma angiotensin I or angiotensin II levels in 
the ACE.3 / mice as compared with littermate wild-type 
mice. For example, angiotensin II levels in the plasma of 
ACE.3_/_ mice averaged 172.4±17.6 pg/mL (n=12) as 
compared with 139.8±23.2 pg/mL in ACE.3+/+ mice (n= 13).
The finding that ACE.3 / mice have normal plasma levels 
of angiotensin II and a normal blood pressure suggests that 
ectopic expression of ACE within the liver provides sufficient 
enzymatic activity to allow physiologically appropriate pro­
duction of angiotensin II. This hypothesis predicts that 
ACE.3 / animals should respond to ACE inhibitors with a 
reduction of blood pressure. To test this, a cohort of ACE.3 
mice and littermate wild-type mice were treated with the 
ACE inhibitor captopril for 5 days (Figure 4B). Blood 
pressure was measured in these animals before, during, and 
after captopril administration. This study showed no differ­
ence in the response of wild-type and ACE.3_/_ mice to the 
administration of an ACE inhibitor. On cessation of captopril, 
the blood pressures of both groups of animals rapidly re­
turned to control levels. This experiment showed that the 
normal blood pressure observed in A C E . 3 m i c e  is directly 
dependent on the ACE activity present in these animals.
Dehydration is associated with an activation of the renin- 
angiotensin system. To investigate if ACE.3_/_ mice were 
able to tolerate dehydration, 6 knockout mice and 6 wild-type 
mice were not allowed water for 24 hours. Blood pressure, 
heart rate, and body weight were measured at 12, 16, 20, and
24 hours of water deprivation. No statistically significant 
differences were observed between wild-type and ACE.3 / 
mice during the course of the dehydration. For example, 24 
hours of dehydration produced no statistical reduction of 
systolic blood pressure in either wild-type or ACE.3_/_ mice. 
Also, both groups lost an equivalent percentage of body 
weight (wild-type, 9.3±0.7% versus ACE.3_/_, 9.8±1.3%). 
Thus, ACE.3 / mice tolerate dehydration for 24 hours in a 
fashion seemingly equivalent to wild-type mice.
Mice null for all ACE expression produce large amounts of 
a dilute urine.12 In part, this is due to underdevelopment of 
the renal medulla and papilla, a finding also observed in 
angiotensinogen and ATr receptor knockout mice.13-16 To 
study the renal concentrating ability of ACE.3 / mice, these 
animals were water deprived and placed in metabolic cages 
for a 24-hour quantitation of urinary volume and urine 
osmolality. Twelve wild-type ( / ) mice, 11 / mice, and
13 —I— mice produced an average volume of 403±64, 
473 93, and 403 100 L of urine, respectively, whereas the 
osmolality of the urine was 2162±253 (+ /+ ), 2080±213 
(+ /—), and 2373±252 (—/—) mOsm/kg H2O. This experi­
ment showed that ACE.3 / mice concentrated urine in a 
fashion equivalent to that of wild-type mice. Indeed, evalua­
tion of ACE.3 / mice has verified that they can concentrate 
to greater than 3000 mOsm/kg H2O when a drop of urine is 
examined after 24 hours of water deprivation. Histological 
examination of the kidneys from ACE.3 / mice showed no 
anatomic lesions. ACE.3 / mice have a serum creatinine and 
blood urea nitrogen equivalent to that of wild-type mice.
An unexpected finding noticed in ACE knockout mice was 
the presence of anemia.7 Examination of ACE.3 / mice 
showed a hematocrit of 52±0.5% (n= 17), which was equiv-
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Figure 3, ACE immunohistochemistry. Tissues from wild-type 
(+/+) and ACE.3 knockout ( - / - )  mice were prepared and 
stained with rabbit anti-ACE antibody. A and B, Sections of 
liver. The high-power insert in B shows abundant ACE within the 
cell membranes of hepatocytes. Despite this, the overall histo­
logical appearance of ACE.3"'" liver was unchanged from that 
of wild-type liver. C and D, Sections of lung. Wild-type mice 
have abundant pulmonary ACE. In contrast, the lung from 
ACE.3"' mice has no detectable ACE. E and F, Sections of kid­
ney. Wild-type kidney has abundant ACE in proximal tubular 
epithelium. In contrast, ACE.3"' mice show much reduced lev­
els of ACE staining within this same tissue. Within the kidney, 
arterioles from wild-type mice have easily observable endothelial 
and adventitial immunoreactivity for ACE (G, arrow indicates en­
dothelium). In contrast, renal arterioles from ACE.3"' mice (H) 
show no such staining. In fact, no endothelial immunoreactivity 
for ACE was present anywhere in ACE.3"' mice. A and B were 
photographed with a 10x objective; C through F, 20x objec­
tive; G, H, and B insert, 100x oil objective.
alent to the hematocrit of 52±0.7% (n=16) measured in 
littermate wild-type mice.
Discussion
One of the goals of this study was to develop a method 
allowing selective tissue expression of ACE. Ultimately, we 
wish to create lines of mice expressing ACE in a variety of 
individual tissues in the absence of generalized tissue expres­
sion. Our first attempt was to make a mouse with expression 
of ACE limited to the liver. The availability of the albumin 
promoter, the very low endogenous levels of ACE expression 
by the liver, and the large size of this organ made this an 
attractive model. Although there are several potential ap­
proaches to creating liver-specific protein expression, our
approach was to use homologous recombination to substitute 
promoter control of the somatic ACE gene from the endog­
enous promoter to the inserted albumin promoter. We hy­
pothesized that such a mouse would express ACE in the liver 
but not in vascular endothelium. For the most part, this 
approach proved successful. ACE.3 / mice have abundant 
hepatic expression of ACE while lacking ACE expression by 
endothelium, adventitia, the gut, and several other tissues that 
normally make this protein. Only in the kidney do we see 
residual somatic ACE expression, and even here, careful 
quantitation showed that ACE.3 / mice made only 12% to 
14% of the renal ACE found in wild-type mice. This residual 
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Figure 4. Systolic blood pressure. A, Basal systolic blood pres­
sure was determined for a cohort of 48 ACE.3 littermate mice 
over 4 consecutive days using an automated tail-cuff manome­
ter. The systolic blood pressure for each mouse (•) is the aver­
age of 80 individual measurements. A solid bar (™ ) represents 
the average for each group of 8 mice. The systolic blood pres­
sure is not different between wild-type (+/+), heterozygous 
(+ /-) , and knockout ( - / - )  mice of either gender. B, Baseline 
blood pressure was established for a cohort of ACE.3 animals. 
Captopril was then added to the drinking water of 6 + /+  (♦) 
and 6 - / -  (■) mice, and systolic blood pressures were moni­
tored daily. After 5 days, the captopril was discontinued with 
blood pressure measurements continuing for 4 additional days. 
During the 9 day experiment, the blood pressure was also moni­
tored for a control group of 4 ACE.3"' mice (■*) that never 
received captopril. In response to captopril, the systolic blood 
pressures of ACE.3"'" and ACE.3"' mice decreased in a similar 
fashion, both in magnitude and duration. Likewise, mice of both 
genotypes exhibited a rapid rebound in blood pressure once 
captopril was discontinued.
Downloaded from circres.ahajournals.org at UNIV OF UTAH on November 2, 2009
92 Circulation Research January 11/25, 2002
albumin promoter in that the original characterization of 
albumin promoter cassettes similar to that used in the 
ACE.3 _/_ mice showed low levels of reporter gene expression 
within the kidney.11
In the ACE.3_/_ model, the total body load of ACE is substantial. 
In a sense, the liver of ACE.3_/_ mice approximates the function of 
the lung in wild-type animals, allowing physiological regulation of 
the renin-angiotensin system in ACE.3_/_ mice to generate appro­
priate levels of angiotensin II. This, in turn, results in a mouse with 
a normal blood pressure and normal renal function.
So what of endothelial ACE? In a wild-type mouse, and in 
a human, endothelium provides a major source of tissue ACE. 
Indeed, studies by Ng and Vane17 showed sufficient ACE in 
the lung to entirely convert blood angiotensin I to angiotensin 
II during a single transit. What we now observe in ACE.3 / 
mice is that, surprisingly, endothelial expression of ACE is 
not obligatory for basal blood pressure regulation; in these 
mice, sufficient ACE expression by a different tissue source 
can compensate for the lack of endothelial ACE. However, 
we must offer a caveat. Current hypotheses concerning the 
renin-angiotensin system implicate the local generation of 
angiotensin II in some of the physiological and pathophysi­
ological effects of this peptide, including aspects of cardio­
vascular and renal injury.5 In this study, we made no attempt 
to quantitate whether ACE expression in ACE.3_/_ mice is 
sufficient for physiological regulation in the face of any form 
of tissue injury. Indeed, a powerful use of ACE.3_/_ mice will 
be to test various models of injury to assess the role of 
endothelial ACE expression. Such studies may reveal specific 
and unique requirements for endothelial ACE expression, but 
under basal conditions, the expression of ACE by the liver is 
capable of substituting for endothelial ACE expression in that 
ACE.3_/_ mice have a normal blood pressure and normal 
renal function.
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